Sometimes, regulators giveth with one hand, and taketh away with the other.
This is what Gilead Sciences (GILD) experienced this week, as the European Commission on Monday approved its CAR-T gene therapy for two aggressive forms of blood cancer. But on Tuesday, the U.K.’s cost-effectiveness watchdog declined to recommend government coverage.
NICE has become slightly too focused on saving money.
Perhaps they should be a little more concerned about the
potential benefits for patients.
What a surprise? The EU says ‘Si!’ The UK say ‘See you’ – later perhaps? It’s just another flavor of Brexit, mayhaps? (Full disclosure – I do not disagree with the position of NICE.)
Comments are closed.